During the corresponding time, Axogen Inc recorded a revenue increase by 23.06 % year on year, sequentially revenue grew by 13.46 %. While revenue at the Axogen Inc 's corporate clients
Axogen Inc's Comment on Sales, Marketing and Customers
Axogen, Inc. operates in the peripheral and central nervous system markets globally through its Axoguard Product Line, which includes the Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap. These products are based on extracellular matrix (ECM) technology originally developed by Evergen (formerly Cook Biotech Incorporated). Distribution rights exclude use in the oral cavity for endodontic and periodontal applications and oral maxillofacial surgery related to dental, soft, or hard tissue repair or reconstruction. Axogen holds a Distribution Agreement with Evergen for these products, effective until December 31, 2030. Customers and related entities mentioned in filings include Axogen, Inc., Cook Biotech Incorporated, Evergen, and RTI Surgical, Inc.
In a groundbreaking move, Axogen, Inc., a leading player in the field of innovative surgical solutions for peripheral nerve injuries, has recently announced the full launch of their newest product, Avive+ Soft Tissue Matrix. This resorbable, multi-layer amniotic membrane allograft is designed to act as a soft tissue barrier, offering temporary protection and tissue separation during the critical phase of peripheral nerve healing. This exciting development aligns with the U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, as well as U.S. State regulations as a 361 human tissue product.Factual Overview:Axogen, Inc. has m...
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve CapIn recent news, Axogen, Inc. has unveiled promising findings from their clinical trial, REPOSE. The trial evaluated the effectiveness of Axoguard Nerve Cap, a novel medical device, compared to the standard-of-care neurectomy in reducing pain for patients. The results of the trial demonstrate that Axoguard Nerve Cap successfully met its primary endpoint of non-inferiority, showcasing its potential as a viable alternative to standard neurectomy procedures.Neurectomy is a surgical procedure often performed to alleviate chronic, debilitating pain caused by damaged or compressed nerves. Stand...
Axogen Inc’s Comment on Sales, Marketing and Customers
Axogen, Inc. operates in the peripheral and central nervous system markets globally through its Axoguard Product Line, which includes the Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, and Axoguard Nerve Cap. These products are based on extracellular matrix (ECM) technology originally developed by Evergen (formerly Cook Biotech Incorporated). Distribution rights exclude use in the oral cavity for endodontic and periodontal applications and oral maxillofacial surgery related to dental, soft, or hard tissue repair or reconstruction. Axogen holds a Distribution Agreement with Evergen for these products, effective until December 31, 2030. Customers and related entities mentioned in filings include Axogen, Inc., Cook Biotech Incorporated, Evergen, and RTI Surgical, Inc.
Sources:
Axogen inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Axogen inc’s corporate clients.
For your research, we’ve provided 9 tables on Axogen inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
185.19 %